These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1606 related items for PubMed ID: 11759645

  • 1. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 20; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 4. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, Valsartan Heart Failure Trial Investigators.
    Circulation; 2003 Sep 16; 108(11):1306-9. PubMed ID: 12939207
    [Abstract] [Full Text] [Related]

  • 5. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 16; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 6. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 16; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 7. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L, Iannazzo S, Zaniolo O.
    Am J Cardiovasc Drugs; 2009 Jun 16; 9(6):383-92. PubMed ID: 19929036
    [Abstract] [Full Text] [Related]

  • 8. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 9. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.
    Am Heart J; 2004 Dec 15; 148(6):951-7. PubMed ID: 15632877
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Tepper D.
    Congest Heart Fail; 2002 Dec 15; 8(1):57-8. PubMed ID: 11821630
    [No Abstract] [Full Text] [Related]

  • 11. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K, Salukhe TV, Coats AJ, Mayet J, Piepoli M, Francis DP.
    Int J Cardiol; 2004 Feb 15; 93(2-3):105-11. PubMed ID: 14975535
    [Abstract] [Full Text] [Related]

  • 12. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 15; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 13. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 14. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
    N Engl J Med; 1999 Sep 02; 341(10):709-17. PubMed ID: 10471456
    [Abstract] [Full Text] [Related]

  • 15. [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
    Piérard L.
    Rev Med Liege; 2002 Jan 02; 57(1):57-9. PubMed ID: 11899501
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis MV.
    Am Heart J; 2003 Nov 02; 146(5):E17. PubMed ID: 14597946
    [Abstract] [Full Text] [Related]

  • 17. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators (Valsartan Heart Failure Trial).
    J Am Coll Cardiol; 2002 Oct 16; 40(8):1414-21. PubMed ID: 12392830
    [Abstract] [Full Text] [Related]

  • 18. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 19. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, Val-HeFT Investigators.
    Congest Heart Fail; 2010 Feb 21; 16(5):191-5. PubMed ID: 20887614
    [Abstract] [Full Text] [Related]

  • 20. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.